Our data could warrant interventional trials investigating the efficacy of drugs with anti-fibrotic properties such as mineralocorticoid receptor antagonists on diabetic neuropathy [39], as these drugs have shown to improve CAN indices in other populations with congestive heart failure [40] and kidney disease [41]. This evidence concerns the gene NR3C2 and kidney disorder.